Business
Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Further Strengthens Scientific Advisory Board With Appointment of Dr. Dan J. Stein
TORONTO, March 25, 2025 (GLOBE NEWSWIRE) -- Psyence Group Inc ("Psyence Group" or the "Company") (CSE: PSYG) is pleased that its NASDAQ-listed associate, Psyence Biomedical Ltd (NASDAQ: PBM) ("PBM" or "Psyence Biomed"), has announced that it has expanded its newly created Scientific Advisory Board (SAB) with the addition of Dr. Dan J. Stein, a recognized leader in the field of psychopharmacology. According to a news release issued by PBM, Dr. Stein is the Professor and Chair of the Dept of Psych
About this update from Psyence Group Inc.
[{"type":"image","alt":"Psyence Group Inc.","displaySize":"","headline":null,"caption":"Psyence Group Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":73,"url":"https://media.zenfs.com/en/globenewswire.com/8c61cc4f84552088a0a6295425fca09b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/sdhaxmIhcyMdinSoiDyBzA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwMjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/8c61cc4f84552088a0a6295425fca09b","width":300,"height":73}},"lazy":false},{"type":"text","content":"TORONTO, March 25, 2025 (GLOBE NEWSWIRE) -- Psyence Group Inc ("Psyence Group" or the "Company") (CSE: PSYG) is pleased that its NASDAQ-listed associate, Psyence Biomedical Ltd (NASDAQ: PBM) ("PBM" or "Psyence Biomed"), has announced that it has expanded its newly created Scientific Advisory Board (SAB) with the addition of Dr. Dan J. Stein, a recognized leader in the field of psychopharmacology.","length":439,"tagName":"p"},{"type":"text","content":"According to a news release issued by PBM, Dr. Stein is the Professor and Chair of the Dept of Psychiatry and Mental Health at the University of Cape Town (UCT) and Director of the South African Medical Research Council (MRC) Unit on Risk & Resilience in Mental Disorders. Dr. Stein will work closely with SAB chairman, Albert P. Garcia-Romeu, Ph.D, an Associate Professor in the Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine. The PBM news release goes on to state that in addition to the continuation of PBM's Phase IIb clinical trial of psilocybin as a potential treatment for Adjustment Disorder in Palliative Care, PBM will also be advancing plans for its second development indication in Alcohol Use Disorder, introducing an entirely new class of psilocybin-based therapeutics to address significant unmet needs in mental health and addiction.","length":904,"tagName":"p"},{"type":"text","content":"PBM will discuss the role of the SAB in a corporate webinar scheduled for Thursday, April 10, 2025, at 12:00 p.m. EST, during which the executive team will also discuss PBM's broader vision for the future of psychedelic therapeutics.","length":237,"tagName":"p"},{"type":"text","content":"To register for the corporate webinar, please access the following link: Psyence Biomed Corporat...